Your Care Team and Quality of Life
At a Glance
Melanoma-associated leptomeningeal disease is best managed by a coordinated team that treats the cancer, neurological problems, pressure-related symptoms, and daily quality of life. A shunt may relieve hydrocephalus symptoms but does not treat the melanoma itself.
Managing leptomeningeal disease (LMD) is a team effort. Because this condition affects both your nervous system and your overall cancer status, you will likely work with a group of specialists who coordinate your care across different fields of medicine. This “multidisciplinary” approach ensures that while one doctor focuses on the cancer cells, another focuses on protecting your brain and spine, and a third focuses on your comfort and daily function [1]. Lack of access to a major center does not mean your current clinicians cannot provide meaningful care; resources like social work, financial support, and rehabilitation are also available.
Your Core Care Team
A specialized neuro-oncology team is the gold standard for managing melanoma-associated LMD. This team typically includes:
- Medical/Melanoma Oncologist: Your primary cancer doctor who manages systemic treatments like immunotherapy or targeted therapy [2].
- Neuro-Oncologist: A specialist who focuses specifically on cancers of the brain and nervous system. They help interpret complex spinal fluid tests and coordinate neurological care [3].
- Neurosurgeon: A surgeon who performs procedures to manage fluid buildup or to place “ports” (Ommaya reservoirs) for direct drug delivery into the spinal fluid [4][5].
- Radiation Oncologist: A doctor who uses targeted radiation to treat bulky disease or relieve pain in the spine [6].
- Neuroradiologist: A specialist who reads your MRI scans, focusing on the subtle signs of LMD in the brain and spine [7].
- Supportive Care/Palliative Specialists: These experts focus on managing symptoms like pain, nausea, and anxiety alongside your cancer treatment, ensuring your quality of life is a top priority [5].
The Role of Neurosurgery for Symptom Relief
For many patients with LMD, the most distressing symptoms come not from the cancer cells themselves, but from the pressure they create. As cancer cells clog the natural drainage of cerebrospinal fluid (CSF), the fluid can build up—a condition called hydrocephalus [8].
A neurosurgeon may recommend a shunt (a thin tube) to divert this excess fluid away from the brain and into another part of the body, usually the abdomen [4].
- What it does: A shunt can improve “pressure” symptoms in select observational patients. Research shows that shunting improves headaches in about 72% of patients and nausea/vomiting in about 81% [9]. It can also help with balance and confusion [10].
- What it doesn’t do: A shunt is a supportive procedure; it does not treat or kill the melanoma cells [11]. It also hasn’t been shown to consistently extend survival, though it can make the time you have much more comfortable [12].
- Risks: Shunts do not guarantee improvement. Like any surgery, they carry risks such as infection, mechanical failure where the tube becomes blocked, overdrainage, or bleeding [13][14]. Coordination with your oncologist is necessary if you are receiving intrathecal therapy.
Understanding “Performance Status”
In your medical notes, you may see a score called ECOG or KPS. This is your performance status—a standardized way for doctors to measure how well you are able to perform daily activities [15].
- Why it matters: Your performance status is one of the most important factors in choosing a treatment. Patients with a “good” status (who are still active and mobile) are often eligible for more intensive treatments or clinical trials [16][17]. ECOG is scored from 0 to 5, while KPS uses a 0-to-100 scale.
- The Impact of LMD: LMD can rapidly lower your performance status by causing weakness or confusion. However, if these symptoms are caused by fluid pressure, a shunt might relieve some of the decline [10][12].
- Prognosis: Generally, a better performance status at the time of diagnosis is associated with a better outlook [18].
Systemic Disease and Your Choices
Your care team will also look at how well the melanoma is controlled in the rest of your body (like your lungs or liver).
- Controlled Disease: If your systemic cancer is stable, the team can focus more aggressively on the LMD [19].
- Progressing Disease: If the cancer is growing rapidly in multiple organs, your doctors may prioritize treatments that work throughout the entire body or focus more heavily on comfort and symptom management [20].
Navigating these discussions can be exhausting. Your role is to be honest with your team about your goals—whether that is maximizing time, maintaining independence, or ensuring you are pain-free. This information helps your multidisciplinary team build the right plan for you [21].
Common questions in this guide
Who should be part of my care team for melanoma-associated LMD?
Could a shunt improve headaches or nausea caused by LMD?
What do ECOG and KPS scores tell my doctors?
What risks should I know about before having a shunt?
How does melanoma elsewhere in my body affect LMD treatment?
Can I receive palliative care while still receiving cancer treatment?
Get notified when new evidence is published on leptomeningeal melanoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.
Wilcox JA, Chukwueke UN, Ahn MJ, et al.
Neuro-oncology 2024; (26(10)):1781-1804 doi:10.1093/neuonc/noae103.
PMID: 38902944 - 2
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.
Glitza IC, Smalley KSM, Brastianos PK, et al.
Pigment cell & melanoma research 2020; (33(4)):527-541 doi:10.1111/pcmr.12861.
PMID: 31916400 - 3
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.
Tétu P, Sirven-Villaros L, Cuzzubbo S, et al.
Cancers 2020; (12(9)) doi:10.3390/cancers12092635.
PMID: 32947841 - 4
Surgical Treatment for Leptomeningeal Disease.
Volkov AA, Filis AK, Vrionis FD
Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):47-53 doi:10.1177/107327481702400107.
PMID: 28178712 - 5
Leptomeningeal metastasis.
Taillibert S, Chamberlain MC
Handbook of clinical neurology 2018; (149()):169-204 doi:10.1016/B978-0-12-811161-1.00013-X.
PMID: 29307353 - 6
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.
Khaled ML, Tarhini AA, Forsyth PA, et al.
Cancers 2023; (15(6)) doi:10.3390/cancers15061884.
PMID: 36980770 - 7
Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.
Ozcan G, Singh M, Vredenburgh JJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(1)):11-29 doi:10.1158/1078-0432.CCR-22-1585.
PMID: 35972437 - 8
Lumbar-ventricular cerebrospinal fluid pressure discrepancy in leptomeningeal metastasis associated intracranial hypertension.
Chang KW, Jeon WJ, Lee WJ, et al.
Fluids and barriers of the CNS 2026; (23(1)).
PMID: 42218510 - 9
Cerebrospinal Fluid Shunting in Hydrocephalus Secondary to Leptomeningeal Metastases: A Systematic Review and Meta-Analysis of Functional Outcomes, Symptom Improvement, and Complications.
Alomari O, Uslu I, Kılıç D, et al.
World neurosurgery 2026; (209()):124901 doi:10.1016/j.wneu.2026.124901.
PMID: 41796675 - 10
Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.
Bander ED, Yuan M, Reiner AS, et al.
Journal of neuro-oncology 2021; (154(3)):301-313 doi:10.1007/s11060-021-03827-2.
PMID: 34406564 - 11
Ventriculoperitoneal shunting with an on-off valve for patients with leptomeningeal metastases and intracranial hypertension.
Huntoon KM, Gasco J, Glitza Oliva IC, et al.
Neuro-oncology practice 2024; (11(1)):56-63 doi:10.1093/nop/npad056.
PMID: 38222058 - 12
Survival and quality of life after CSF diversion in adult patients with leptomeningeal metastasis-associated hydrocephalus: a systematic review and meta-analysis.
Dhaliwal J, Ruiz-Perez M, Mihaela-Vasilica A, et al.
Neurosurgical focus 2023; (55(2)):E16 doi:10.3171/2023.5.FOCUS23195.
PMID: 37527677 - 13
Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.
Kim HS, Park JB, Gwak HS, et al.
World journal of surgical oncology 2019; (17(1)):59 doi:10.1186/s12957-019-1595-7.
PMID: 30917830 - 14
Lumboperitoneal and ventriculoperitoneal shunting for leptomeningeal disease-associated hydrocephalus: a systematic review and meta-analysis of postoperative outcomes and comparative effectiveness.
Hajikarimloo B, Mohammadzadeh I, Tos SM, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(10)):4899-4912 doi:10.1007/s10072-025-08321-5.
PMID: 40550976 - 15
Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study.
Aboelatta MA, Rezazadeh A, Sener U, et al.
Melanoma research 2026; (36(3)):203-210 doi:10.1097/CMR.0000000000001088.
PMID: 42053986 - 16
Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics.
Faillot M, Goldwirt L, Jouenne F, et al.
Neurosurgery 2026; (99(4)):882-889 doi:10.1227/neu.0000000000003924.
PMID: 41636506 - 17
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
Long GV, Atkinson V, Lo SN, et al.
The Lancet. Oncology 2025; (26(3)):320-330 doi:10.1016/S1470-2045(24)00735-6.
PMID: 39978375 - 18
Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD, Bindal S, Bassett RL, et al.
Journal of neuro-oncology 2019; (142(3)):499-509 doi:10.1007/s11060-019-03121-2.
PMID: 30847840 - 19
Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.
Saberian C, Milton DR, Simon J, et al.
Neuro-oncology practice 2024; (11(4)):452-463 doi:10.1093/nop/npae026.
PMID: 39006528 - 20
How we treat patients with leptomeningeal metastases.
Le Rhun E, Preusser M, van den Bent M, et al.
ESMO open 2019; (4(Suppl 2)):e000507 doi:10.1136/esmoopen-2019-000507.
PMID: 31231573 - 21
Carcinomatous meningitis: Current insights into diagnosis, prognosis and management.
Gambaretti M, Lavalley A, Ollivier M, et al.
La Revue de medecine interne 2026; doi:10.1016/j.revmed.2026.09.016.
PMID: 42907241
This page is for informational purposes only and does not constitute medical advice. It explains care teams, shunts, performance status, and quality-of-life planning in melanoma-associated leptomeningeal disease; your oncology and neurosurgery teams should interpret your symptoms and recommend care for your situation.